$ESPRNot financial advice.
NASDAQ:ESPR weekly chart
working is way up to the top of this broadening formation. more likely to fill gap on purple box.
Like and follow.
Thanks.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.62 USD
−209.25 M USD
116.33 M USD
195.06 M
About Esperion Therapeutics, Inc.
Sector
CEO
Sheldon L. Koenig
Headquarters
Ann Arbor
Website
Founded
1998
FIGI
BBG004KB3S72
Esperion Therapeutics, Inc. is a pharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.
ESPR BULLISHEsperion Therapeutics (NASDAQ: ESPR), priced at $1.68 as of September 27, focuses on creating medications for cardiovascular and cardiometabolic diseases. They've launched products like NEXLETOL and NEXLIZET, which help lower LDL cholesterol in adults. Recently, 26 hedge funds held about $98.59 mill
ESPR - Momentum Biotech PlayEsperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializi
ESPR - Approval of NEXLETOL (Cardiovascular Diseases)Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializi
ESPR a penny and medtech stock LONGESPR on the 120-minute chart is surging with momentum from an FDA approval for a new
cholestrol and lipid medication which will be an alternative to the at statin class which has
side effects and can cause diabetes. I am familar with a few of the professionals on the
science advisory board they a
$ESPR Esperion Therapeutics Inc. NASDAQ:ESPR Esperion Therapeutics Inc.
Long term PTs 39 - 53 - 76 and higher
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempe
Esperion Therapeutics@KalaGhazi
Esperion Therapeutics
Big drop yesterday.
Will it rally or back down again???
ESPR (Esperion Therapeutics) short positionESPR (Esperion Therapeutics) short position
Entry level: $7.93
Take profit: $6.82
Stop loss: $8.48
Preparing for Earnings Season: ESPRStocks that are reporting earnings in 3 to 4 weeks can be monitored for pre-earnings runs.
ESPR had momentum runs recently, as marked by the candlestick patterns within the green rectangles in this chart. A shift of sentiment can be seen in the bottoming pattern with Accumulation/Distribution indi
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
PFE5307022
Esperion Therapeutics, Inc. 4.0% 15-NOV-2025Yield to maturity
6.47%
Maturity date
Nov 15, 2025
Explore more bonds
Frequently Asked Questions
The current price of ESPR is 2.46 USD — it has increased by 5.58% in the past 24 hours. Watch Esperion Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Esperion Therapeutics, Inc. stocks are traded under the ticker ESPR.
ESPR stock has fallen by −35.94% compared to the previous week, the month change is a 16.04% rise, over the last year Esperion Therapeutics, Inc. has showed a 30.85% increase.
We've gathered analysts' opinions on Esperion Therapeutics, Inc. future price: according to them, ESPR price has a max estimate of 16.00 USD and a min estimate of 2.05 USD. Watch ESPR chart and read a more detailed Esperion Therapeutics, Inc. stock forecast: see what analysts think of Esperion Therapeutics, Inc. and suggest that you do with its stocks.
ESPR reached its all-time high on May 21, 2015 with the price of 120.96 USD, and its all-time low was 0.70 USD and was reached on Oct 12, 2023. View more price dynamics on ESPR chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
ESPR stock is 8.94% volatile and has beta coefficient of 3.26. Track Esperion Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Esperion Therapeutics, Inc. there?
Today Esperion Therapeutics, Inc. has the market capitalization of 459.09 M, it has decreased by −19.46% over the last week.
Yes, you can track Esperion Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Esperion Therapeutics, Inc. is going to release the next earnings report on Feb 27, 2025. Keep track of upcoming events with our Earnings Calendar.
ESPR earnings for the last quarter are −0.15 USD per share, whereas the estimation was −0.18 USD resulting in a 14.42% surprise. The estimated earnings for the next quarter are −0.13 USD per share. See more details about Esperion Therapeutics, Inc. earnings.
Esperion Therapeutics, Inc. revenue for the last quarter amounts to 51.63 M USD, despite the estimated figure of 51.31 M USD. In the next quarter, revenue is expected to reach 63.45 M USD.
ESPR net income for the last quarter is −29.52 M USD, while the quarter before that showed −61.92 M USD of net income which accounts for 52.32% change. Track more Esperion Therapeutics, Inc. financial stats to get the full picture.
No, ESPR doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 18, 2024, the company has 240.00 employees. See our rating of the largest employees — is Esperion Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Esperion Therapeutics, Inc. EBITDA is 29.60 M USD, and current EBITDA margin is −133.58%. See more stats in Esperion Therapeutics, Inc. financial statements.
Like other stocks, ESPR shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Esperion Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Esperion Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Esperion Therapeutics, Inc. stock shows the neutral signal. See more of Esperion Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.